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ﬁxation which reduces the level of opsonins. It can co-opt
host proteases to destroy opsonins on the bacterial surface.
Several different pore-forming toxins are secreted, some of
which destroy neutrophils (alpha-toxin and Panton Valen-
tine Leucocidin). If taken up by phagocytic cells S.aureus
can resist intracellular killing mechanisms such as lysozyme,
free oxygen radicals and antimicrobial peptides. S.aureus
can secrete proteins called superantigens which trigger the
activation of T cells in a manner that lacks the speciﬁcity of
antigen presentation. This causes depletion of immune cells
and the failure to mount a robust response with immunolog-
ical memory and may help explain the recurrent nature of
infections. This presentation will review current knowledge
of the phenomena of colopnization and disease pathogen-
esis gathered from studies with many strains of S.aureus.
Reference will be made to CA-MRSA where appropriate.
doi:10.1016/j.ijid.2008.05.123
52.004
Clinical Aspects of the Community-Acquired MRSA
Epidemic
H. Chambers
University of California San Francisco, San Francisco, CA,
USA
Prevalence of methicillin-resistant Staphylococcus
aureus(MRSA) in the community is high and rising both
in the United States and in other countries. USA300 and
USA400, are the predominant community-associated MRSA
(CA-MRSA) clones circulating in US communities. Enhanced
transmissibility and ﬁtness, and hypervirulence characterize
and probably drive emergence of MRSA in the community.
The burden of disease caused by MRSA in the community
exceeds that occurring in hospitals. In addition, community
strains of MRSA are now a major cause of hospital-onset
infections. Identiﬁcation of multiple-drug resistant vari-
ants of community MRSA strains is of particular concern.
Emergence of CA-MRSA has a profound impact on choice of
therapy for treatment of all staphylococcal infections. For
those treated as out-patients, clinicians must increasingly
rely on second line agents, often in the absence of good data
supporting their effectiveness. For hospitalized patients, an
inevitable consequence is even greater use of vancomycin.
This will increase the already considerable pressure for
selection of vancomycin non-susceptible strains. Use of
vancomycin will likely be accompanied by a higher rate of
treatment failure. Several alternative drugs are available
for treatment of MRSA, but none of these has yet been
shown to be superior to vancomycin. The search for new
approaches to prevention and treatment of staphylococcal
infections has never been more important.
doi:10.1016/j.ijid.2008.05.124
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verview Abstract for the Symposium: Partnering in R&D
o develop new drugs for the most neglected diseases
escription: Tropical diseases such as chloroquine-resistant
alaria, leishmaniasis, lymphatic ﬁlariasis, Chagas disease,
uman African trypanosomiasis (HAT), dengue fever, and
chistosomiasis continue to cause signiﬁcant morbidity and
ortality worldwide. With few new treatments that tend to
e unaffordable and poorly adapted to the ﬁeld, physicians
re forced to use old tropical medicines that are increas-
ngly ineffective due to inevitable drug resistance. Together
ith tuberculosis and HIV/AIDS, these disabling and/or life-
hreatening diseases represent an enduring unmet medical
eed and are collectively called ‘‘neglected diseases’’.
Of the 1,556 new drugs approved between 1975 and 2004,
nly 21 (1.3%) were speciﬁcally developed for tropical dis-
ases and tuberculosis, even though these diseases account
or 11.4% of the global disease burden. With exponential
rogress made in the basic knowledge of many infectious
iseases, it is ironic that the drugs currently used to treat
inetoplastid diseases were discovered decades ago. With
ew exceptions, the wealth of basic research knowledge of
hese parasites is not being translated into practical appli-
ations.
Although the R&D landscape has signiﬁcantly changed for
eglected diseases since 2000, the need remains for new
eld-adapted drugs for the kinetoplastid diseases. Founded
n 2003 to address the needs of patients with these most
eglected diseases, DNDi (Drugs for Neglected Diseases
nitiative) is a collaborative, patients’ needs-driven, not-
or-proﬁt drug R&D organization that is currently developing
ew treatments against sleeping sickness (human African
rypanosomiasis, HAT), visceral leishmaniasis (VL), Chagas
isease, and malaria.
The only way to improve control is to develop innovative
ew drugs and diagnostics and ensure they are available to
atients. This symposium aims to review the opportunities
nd challenges ahead in the different phases of research and
evelopment of new drugs for the most neglected diseases.
oi:10.1016/j.ijid.2008.05.125
xtensively Drug-Resistant TB: NewName or New Problem
invited)
4.001
he Epidemiology of XDR TB in KwaZulu Natal South
frica: A New name or a New Problem
. Rustomjee ∗, A. Pym
Medical Research Council, Durban, South Africa
ntroduction: The description of the AIDS-related ‘‘Tugela
erry’’ Outbreak (TFO) of XDR TB in KwaZulu Natal focused
nternational attention on this province of South Africa as
n epicenter of an XDR TB epidemic of unknown proportion.
imilarly the global burden of TB drug-resistance, particu-
arly in countries with the highest incidence of HIV and TB is
